真实世界的茵栀黄颗粒临床联合用药特征分析

doi:10.19803/j.1672-8629.2021.08.02

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (8): 705-709.
DOI: 10.19803/j.1672-8629.2021.08.02

• 基于真实世界的中成药联合用药方案研究专栏 • 上一篇下一篇

真实世界的茵栀黄颗粒临床联合用药特征分析

张利丹¹, 谢雁鸣^1,*, 谢瑀婷²

¹中国中医科学院中医临床基础医学研究所,北京 100700;
²中国人民大学统计学院,北京 100872

收稿日期:2021-02-18 出版日期:2021-08-15 发布日期:2021-08-17
通讯作者: ^*谢雁鸣,女,首席研究员·博导,中医临床评价方法。E-mail: ktzu2018@163.com
作者简介:张利丹,女,硕士,中药上市后评价。
基金资助:
国家重点研发计划（2018YFC1707400）

Characteristics of Clinical Combination with Yinzhihuang Granules in the Real World

ZHANG Lidan¹, XIE Yanming^1,*, XIE Yuting²

¹Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China;
²School of Statistics, Renmin University of China, Beijing 100872, China

Received:2021-02-18 Online:2021-08-15 Published:2021-08-17

摘要/Abstract

摘要： 目的深入分析真实世界中使用注射用茵栀黄颗粒患者的用药特征,为茵栀黄颗粒在临床中的合理用药及科学研究提供参考。方法基于真实世界电子医疗病历系统（hospital information system,HIS）,提取使用茵栀黄颗粒用药患者诊疗数据,对患者基本信息、诊断信息等进行描述性分析,并通过Apriori算法关联规则的分析方法对合并用药深入挖掘,探索临床实践中茵栀黄颗粒的使用规律。结果提取2010年6月15日至2016年6月15日全国21家三甲医院5 310例使用注射用茵栀黄颗粒用药患者数据纳入研究,男性多于女性,以45~65岁为最多,真实世界中茵栀黄颗粒的使用大多数在说明书规定范围内。使用茵栀黄注射液常见疾病分别为新生儿高胆红素血症、肺结核和乙型病毒性肝炎,常见的用药方案为茵栀黄颗粒+苦黄注射液/柴胡注射液+甘草酸、吡嗪酰胺合并使用利福平和乙胺丁醇基础上,联用康复新液。结论本研究揭示了使用茵栀黄颗粒患者在真实世界中的临床用药现状,适应证与使用剂量基本符合相关指南,探索发现了2种临床常用治疗方案,在促进茵栀黄颗粒的临床合理用药等方面具有参考价值。

关键词: 茵栀黄颗粒, 真实世界, 临床特征, 关联规则

Abstract: Objective To analyze the way Yinzhihuang granules for injection are used in the real world in order to provide reference for rational drug use. Methods Based on the real world electronic medical record system (hospital information system, HIS), the data on diagnosis and treatment of patients treated with Yinzhihuang granules was retrieved while the basic information of patients and diagnosis was analyzed descriptively. The combined use of related drugs was mined using association rules of the Apriori algorithm to explore how Yinzhihuang granules were used in clinical practice. Results A total of 5310 patients treated with Yinzhihuang granules for injection in 21 tertiary hospitals between June 2010 and June 2016 were included in the study. Male patients outnumbered female ones. Most of them were aged 45 to 65. The common diseases treated with Yinzhihuang injection were neonatal hyperbilirubinemia, pulmonary tuberculosis and viral hepatitis B. The common drug regimens were Yinzhihuang granules plus Kuhuang injection / Chaihu injection plus glycyrrhizic acid and pyrazinamide combined with rifampicin and ethambutanol. Conclusion The indications and dosage related to Yinzhihuang granules are basically in line with the relevant guidelines. Two common clinical treatment schemes have been found, which are of referential value in promoting the rational use of Yinzhihuang granules.

Key words: Yinzhihuang granules, real world, clinical features, association rules

中图分类号:

R994.11

张利丹, 谢雁鸣, 谢瑀婷. 真实世界的茵栀黄颗粒临床联合用药特征分析[J]. 中国药物警戒, 2021, 18(8): 705-709.

ZHANG Lidan, XIE Yanming, XIE Yuting. Characteristics of Clinical Combination with Yinzhihuang Granules in the Real World[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 705-709.

参考文献

[1] Li ZH, Xie CC, Tao DY.Clinical observation of Yinzhihuang granules in the treatment of neonatal pathological jaundice[J]. China Practical Medicine(中国实用医药), 2020, 15(27): 14-16.
[2] Zhuang Y, Xie BT, Weng SX, et al.Discussion on the design method of HIS "real world" integrated data warehouse after the market of traditional Chinese medicine[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2011, 36(20): 2880-2882.
[3] World Health Organization.International Statistical Classification of Diseases and Related Health Problems (Tenth Revised Edition) [M]. 2nd ed. Beijing: People's Medical Publishing House, 2008.
[4] Yaozhi data. Drug ATC code query system [EB/OL].[2021-04-26]. https://db.yaozh.com/atc/.
[5] Zhu WF.Diagnostics of Traditional Chinese Medicine(中医诊断学)[M]. Beijing: China Traditional Chinese Medicine Publishing House, 2010: 5.
[6] Kou X.68 cases of neonatal jaundice treatment and clinical analysis[J]. Chinese and Foreign Health Digest(中外健康文摘), 2011, 8(5): 103-104.
[7] Oral Liquid Clinical Research Collaboration Group. A multicenter randomized controlled study of Yinweihuang oral liquid in the treatment of full-term neonates with hyperindirect bilirubinemia[J]. Chinese Journal of Pediatrics(中华儿科杂志), 2011, 49(9): 663-668.
[8] Li X, Tang Y, Li QY.Observation on the curative effect of Yinweihuang injection in the treatment of neonatal delayed jaundice[J]. Chinese Journal of Child Health Care(中国儿童保键杂志), 2006, 14(2): 205-206.
[9] Hu RB, Xu CM, Zhao ZG.The use of drugs beyond the drug label and its international experience and thinking[J]. Drug Evaluation(药品评价), 2012, 9(2): 6-10.
[10] Huang J.Ethical research on the use of over-instruction drugs[J]. Chinese Medical Ethics(中国医学伦理学), 2011, 24(1): 6-8.
[11] Jiang B, Li YP, Xing DJ.Observation of the curative effect of Kuhuang injection on viral hepatitis[J]. Chinese Medical Guide(中国医药指南), 2004, 2(12): 988-989.
[12] Yang BS, Ma YJ, Chen LY, et al.Study on the protective effect and mechanism of compound glycyrrhizin on fulminant liver failure in mice[J]. Chinese Journal of Infectious Diseases(中华传染病杂志), 2005, 23(1): 19-23.
[13] Liu J, Fu SL, Yang ZW.The effect of Kuhuang injection combined with licorice preparation in the treatment of jaundice and hepatitis[J]. Medical Theory and Practice(医学理论与实践), 2019, 32(8): 1162-1163.
[14] Ye XL.Effect analysis of compound glycyrrhizinate monoamine S combined with Kuhuang injection in the treatment of viral hepatitis hyperbilirubinemia[J]. Chinese Medical Guide(中国医药指南), 2017, 15(12): 184.
[15] Li XR, Li YM, Song Y, et al.Clinical observation of Kuhuang injection combined with compound glycyrrhizin in the treatment of 30 cases of acute eczema[J]. Jiangsu Traditional Chinese Medicine(江苏中医药), 2011, 43(4): 50-52.
[16] Li YM, Liu ZZ.Blood concentration control strategy and effect analysis of different anti-tuberculosis drugs[J]. China Prescription Drugs(中国处方药), 2020, 18(9): 38-39.
[17] Yin YT, Chen P.Study on the clinical effect of Kangfuxin liquid bronchoscope lavage in the treatment of multi-drug resistant pulmonary tuberculosis[J]. Modern Medicine and Health(现代医药卫生), 2020, 36(24): 3986-3988.

真实世界的茵栀黄颗粒临床联合用药特征分析

Characteristics of Clinical Combination with Yinzhihuang Granules in the Real World

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	史卜文, 李利寻, 谢雁鸣, 王志飞, 王淇. 真实世界喜炎平注射液治疗3846例细菌性肠道感染患者临床用药特征分析[J]. 中国药物警戒, 2023, 20(9): 1017-1021.
[2]	赵燕, 刘文博, 赵一飞, 李栋, 郑立佳, 宋雅娜, 赵玉娟, 董放. 患者登记研究应用于医疗器械监管科学的实践研究与思考[J]. 中国药物警戒, 2023, 20(4): 423-427.
[3]	杜莹, 谢雁鸣, 王连心, 耿洪娇, 李向杰. 真实世界连花清瘟胶囊（颗粒）适应证人群临床特征及联合用药分析[J]. 中国药物警戒, 2023, 20(3): 296-300.
[4]	杜莹, 赵晓晓, 谢雁鸣, 余小康. 基于真实世界使用榄香烯乳状注射液影响肝功能的倾向性评分分析[J]. 中国药物警戒, 2023, 20(2): 191-195.
[5]	王嘉熙, 郭代红, 张博, 李伯妍, 郭海丽. 116097例氟比洛芬酯用药人群的急性肾损伤自动监测研究及危险因素分析[J]. 中国药物警戒, 2023, 20(2): 201-205.
[6]	吴昀效, 于玥琳, 王胜锋, 孙凤, 孟若谷, 詹思延. 真实世界数据在疫苗上市后安全性主动监测中适用性评价分析[J]. 中国药物警戒, 2023, 20(10): 1081-1089.
[7]	苏鑫鑫, 赵晓晓, 谢雁鸣. 榄香烯乳注射液治疗肝癌患者的真实世界联合用药分析[J]. 中国药物警戒, 2022, 19(9): 929-934.
[8]	黄艳丽, 谢雁鸣, 王连心, 孙粼希, 刘峘, 庄鋆妮. 真实世界老年患者使用刺五加注射液的临床分析[J]. 中国药物警戒, 2022, 19(9): 935-939.
[9]	赵晓晓, 谢雁鸣, 王连心. 真实世界榄香烯乳状注射液治疗肺癌临床应用特征研究[J]. 中国药物警戒, 2022, 19(9): 940-946.
[10]	谭畅, 赵晓晓, 支英杰, 王连心, 谢雁鸣. 榄香烯乳状注射液治疗脑瘤人群临床特征及联合用药的复杂网络分析[J]. 中国药物警戒, 2022, 19(9): 947-953.
[11]	杜莹, 王志飞, 谢雁鸣, 王连心, 李利寻, 刘志帅. 喜炎平注射液治疗手足口病人群的联合用药方案复杂网络分析[J]. 中国药物警戒, 2022, 19(8): 839-844.
[12]	董晗硕, 孙莉, 赵晓晓, 王连心, 余小康, 谢雁鸣. 真实世界榄香烯乳状注射液用于老年人群的临床特征及联合用药分析[J]. 中国药物警戒, 2022, 19(8): 845-850.
[13]	张宏伟, 黎元元, 谢雁鸣, 马晓昌, 王连心, 魏瑞丽, 孙粼希, 徐鸿燕, 庄严. 真实世界中丹参川芎嗪注射液联合用药特征研究[J]. 中国药物警戒, 2022, 19(8): 851-856.
[14]	张蕾, 黎元元, 谢雁鸣, 王连心, 杨晓晨. 注射用灯盏花素治疗心绞痛真实世界研究[J]. 中国药物警戒, 2022, 19(8): 857-861.
[15]	姚羽, 黎元元, 魏戌, 谢雁鸣, 王志飞, 高明慧. 真实世界中鹿瓜多肽注射液疑似过敏反应影响因素研究[J]. 中国药物警戒, 2022, 19(7): 740-743.